Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation." ...
The final major drugmaker President Donald Trump had pressed to accept a most-favored-nation deal has signed an agreement ...
Recent GlobalData POLI analysis showed a 35% decline in pharmaceutical launches across Europe in the ten months after the ...
Trump’s new big pharma deal announced today aims to lower drug prices nationwide, expand Medicaid savings, and cut costs for ...
Today, President Donald J. Trump announced the 17th agreement with a major pharmaceutical manufacturer, Regeneron, to lower prescription drug prices that Americans pay for some of the world’s most ...
With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...
Hosted on MSN
Pharma R&D set to endure despite rising MFN costs
Pharmaceutical research and development (R&D) is unlikely to be significantly impacted by most favored nation (MFN) pricing, according to industry experts. The US bears the highest drug costs globally ...
Most Favored Nation (MFN) drug pricing is just price controls by another name. Instead of openly capping what a drug can cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results